Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dovitinib in advanced urothelial carcinoma
NCT00790426Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2010
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of dovitinib in urothelial carcinoma (UC), sponsored by Novartis. Started Mar 2010; status: completed.
02
Drugs
dovitinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT00790426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00790426.